Literature DB >> 27311919

Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.

Shang-Wen Chen1,2,3, Ying-Chun Lin1,4, Rui-Yun Chen5, Te-Chun Hsieh6,7, Kuo-Yang Yen6,7, Ji-An Liang1,8, Shih-Neng Yang1,7, Yao-Ching Wang1, Ya-Huey Chen9,10, Nan-Haw Chow11, Chia-Hung Kao12,13.   

Abstract

BACKGROUND: This study examined genomic factors associated with a reduction in 18fluoro-2-deoxy-D-glucose (FDG) uptake during positron emission tomography-computed tomography (PET-CT) for definitive chemoradiotherapy (CRT) in patients with pharyngeal cancer.
METHODS: The pretreatment and interim PET-CT images of 25 patients with advanced pharyngeal cancers receiving definitive CRT were prospectively evaluated. The maximum standardized uptake value (SUVmax) of the interim PET-CT and the reduction ratio of the SUVmax (SRR) between the two images were measured. Genomic data from pretreatment incisional biopsy specimens (SLC2A1, CAIX, VEGF, HIF1A, BCL2, Claudin-4, YAP1, MET, MKI67, and EGFR) were analyzed using tissue microarrays. Differences in FDG uptake and SRRs between tumors with low and high gene expression were examined using the Mann-Whitney test. Cox regression analysis was performed to examine the effects of variables on local control.
RESULTS: The SRR of the primary tumors (SRR-P) was 0.59 ± 0.31, whereas the SRR of metastatic lymph nodes (SRR-N) was 0.54 ± 0.32. Overexpression of HIF1A was associated with a high iSUVmax of the primary tumor (P < 0.001) and neck lymph node (P = 0.04) and a low SRR-P (P = 0.02). Multivariate analysis revealed that patients who had tumors with low SRR-P or high HIF1A expression levels showed inferior local control.
CONCLUSION: In patients with pharyngeal cancer requiring CRT, HIF1A overexpression was positively associated with high interim SUVmax or a slow reduction in FDG uptake. Prospective trials are needed to determine whether the local control rate can be stratified using the HIF1A level as a biomarker and SRR-P.

Entities:  

Keywords:  18Fluoro-2-deoxy-D-glucose; Chemoradiotherapy; Head and neck cancer; Hypoxia-inducible factor 1α; Positron emission tomography

Mesh:

Substances:

Year:  2016        PMID: 27311919     DOI: 10.1007/s00259-016-3436-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Authors:  Juliano J Cerci; Luís F Pracchia; Camila C G Linardi; Felipe A Pitella; Dominique Delbeke; Marisa Izaki; Evelinda Trindade; José Soares; Valeria Buccheri; José C Meneghetti
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 3.  The altered metabolism of tumors: HIF-1 and its role in the Warburg effect.

Authors:  Marion Stubbs; John R Griffiths
Journal:  Adv Enzyme Regul       Date:  2009-11-06

4.  Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer.

Authors:  Shih-Chieh Lin; Chih-Ying Liao; Chia-Hung Kao; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Ji-An Liang; Shang-Wen Chen
Journal:  J Radiat Res       Date:  2012-05-11       Impact factor: 2.724

5.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.

Authors:  Maria Hentschel; Steffen Appold; Andreas Schreiber; Nasreddin Abolmaali; Andrij Abramyuk; Wolfgang Dörr; Joerg Kotzerke; Michael Baumann; Klaus Zöphel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

6.  Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV).

Authors:  H Wanebo; P Chougule; N Ready; H Safran; W Ackerley; R J Koness; R McRae; P Nigri; L Leone; K Radie-Keane; P Reiss; T Kennedy
Journal:  Ann Surg Oncol       Date:  2001-09       Impact factor: 5.344

7.  p53 and Ki-67 as markers of radioresistance in head and neck carcinoma.

Authors:  Christian Couture; Hélène Raybaud-Diogène; Bernard Têtu; Isabelle Bairati; Danielle Murry; Josée Allard; André Fortin
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

8.  FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.

Authors:  Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

Review 9.  PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

10.  18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.

Authors:  Tzu-Chen Yen; Lai-Chu See; Chyong-Huey Lai; Chou Wu Yah-Huei; Koon-Kwan Ng; Shih-Ya Ma; Wuu-Jyh Lin; Jenn-Tzong Chen; Wen-Jie Chen; Chiung-Ru Lai; Swei Hsueh
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.